PO-78 | No changes in blood pressure assessed with the 24-hour Holter monitoring in patients treated with anti-CGRP monoclonal antibodies: a prospective observational study (SAFHYPER)
Flavia Lo Castro,1 Niccolò Bonini,2 Luigi Francesco Iannone,1,3 Alberto Boccalini,1 Daria Brovia,1 Luca Pani,1,3 Giuseppe Boriani,2,3 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Cardiology Division, AOU Policlinico di Modena, Modena, Italy; 3Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Migraine is associated with an increased cardiovascular risk, including hypertension. Anti-CGRP/R monoclonal antibodies (mAbs) are effective preventive treatments for migraine, but concerns have been raised about their potential hypertensive effects. Evidence from 24-hour blood pressure (BP) monitoring, a more reliable method than outpatient measurements, is lacking. This study aimed to assess early changes in BP after initiating anti-CGRP/R mAbs in patients with episodic migraine using 24-hour Holter monitoring.
Methods: We conducted a prospective, single-center, real-world study including 20 patients with episodic migraine treated with anti-CGRP/R mAbs. Participants underwent 24-hour Holter BP monitoring before treatment and four weeks after the first injection. Primary outcome was the change in mean systolic BP (SBP). Secondary outcomes included changes in diastolic BP (DBP), differential BP, diurnal/nocturnal values, heart rate (HR), and dipping patterns.
Results: Mean 24-hour SBP and DBP showed non-significant reductions after treatment (−2.4 mmHg and −1.8 mmHg, respectively). No significant changes were found in diurnal BP, while a trend toward improved nocturnal BP control and increased frequency of physiological dipping patterns was observed (from 45% to 85%). HR remained unchanged. No adverse events were reported.
Conclusion: Anti-CGRP/R mAbs did not significantly alter 24-hour BP in the early treatment phase in patients with episodic migraine. These findings support the short-term cardiovascular safety of anti-CGRP/R mAbs, though further studies with larger cohorts and longer follow-up are warranted.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.